HZHuanping Zhang

Huanping Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huanping Zhang has a total of 137 co-authors. Here are the top co-authors by number of shared publications:

  • Ping-Chang Yang

    Institute of Allergy & Immunology Shenzhen University Shenzhen China

    3 shared publications
  • Xiaoxue Chen

    Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, 030032, China

    3 shared publications
  • Aizhi Zhang

    Department of Critical Care Medicine, Second Hospital of Shanxi Medical University, Taiyuan, China

    2 shared publications
  • Hua Xie

    The Respiratory and Allergic Disease Diagnosing Management Center of the PLA. General Hospital of Northern Theater Command, Shenyang, Liaoning, China

    2 shared publications
  • Jing Li

    Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University

    2 shared publications
  • Kai Yin

    Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, 030032, China

    2 shared publications

Latest Publications

  • Artemisia annua Sublingual Immunotherapy Is Efficacious and Well Tolerated in Patients With Season Allergic Rhinitis: A Prospective, Open‐Label, Multicenter Phase IV Trial

    by Yunbo Gao, Xueyan Wang, Jinmei Xue, Xiaoyue Wang, Huanping Zhang, Shuxin Wen, Fang Quan, Zhimin Xing, Boqian Wang, Luo Zhang, et al.

    Background: Artemisia pollen is a major allergen of seasonal allergic rhinitis (SAR) in northern China. Although Artemisia annua sublingual immunotherapy (SLIT) has been approved for treating SAR, large‐scale and long‐term evidence regarding its efficacy, durability, safety, and immunological mechanisms remains limited. Methods: This prospective, open‐label, multicenter phase IV clinical trial was conducted across eight centers in northern China. Adults with A. annua ‐induced SAR received SLIT for two consecutive pollen seasons (Y1, Y2), followed by 1‐year post‐treatment observation (Y3). The primary endpoint was the combined symptom and medication score (CSMS) during the peak pollen period (PPP). Secondary endpoints included individual nasal and ocular symptoms, medication use, and safety outcomes. Exploratory analyses assessed immunoglobulin profiles in serum and nasal secretions and serum inflammatory protein profiles using Olink proteomics. Results: Among 316 patients included in the full analysis set, CSMS decreased significantly from last autumn (Y0, 4.03 ± 0.75) to the Y1 PPP (1.74 ± 0.92, p < 0.0001) and Y2 PPP (1.25 ± 0.74, p < 0.0001) during treatment, and remained stable during the Y3 PPP (1.34 ± 0.93, p = 0.7864) with no significant rebound in symptoms or medication use. SLIT also significantly reduced nasal and ocular symptoms and increased the proportion of medication‐free days during the PPP. Serum total IgE showed a transient increase in Y1 and returned to baseline by Y2, while sIgA and sIgG4 increased in both serum and nasal secretions, with an early and significant rise in the sIgA/sIgE ratio in the nasal secretions in Y1. Proteomic analysis identified dynamic regulation of inflammation‐related proteins, including downregulation of CCL3, IL‐8, OSM, and ST1A1 during long‐term treatment. A. annua SLIT was well tolerated, with most adverse events being mild and self‐limiting. Conclusions: Artemisia annua SLIT is a safe and effective treatment for A . annua ‐induced SAR. Two years of SLIT achieved durable symptom control with reduced medication use, accompanied by immunological signatures of enhanced local immune tolerance and attenuated chronic inflammation.

  • Open Access

    Environmental and occupational risks in asthma burden: A global analysis of trends, disparities, and future projections for ages 5–39

    by Ning Wang, Lei Li, Xing Yang, Kai Yin, Xiaoxue Chen, Qi Yao, Huanping Zhang

  • Open Access

    Unlocking the potential of bronchoalveolar lavage: a promising supplement therapy for moderate-to-severe allergic asthma

    by Minghui Yu, Lu Zhang, Zhigang Pang, Minna Liu, Rou Liu, Qi Yao, Kai Yin, Xiaoxue Chen, Lei Li, Huanping Zhang

    Bronchoalveolar lavage holds potential therapeutic value for moderate-to-severe asthma that is poorly controlled with standard nebulizer therapy. To evaluate the efficacy and safety of bronchoalveolar lavage (BAL) as an adjunctive therapy in patients with moderate-to-severe allergic asthma inadequately controlled by standard inhaled corticosteroids and long-acting beta₂-agonists therapy. In this retrospective study conducted between July 2021 and December 2024, eligible patients were allocated to a control group receiving standard high-pressure nebulizer therapy or a study group receiving additional BAL. Outcomes included changes in asthma symptom scores, pulmonary function, fractional exhaled nitric oxide (FeNO) levels, adverse events, and bronchoalveolar lavage fluid pathogen distribution. The study group demonstrated significantly greater improvement in subjective symptom scores and small airway function parameters compared to controls (P < 0.05). This superiority was particularly pronounced in a predefined subgroup with more severe impairment (FEV1% pred < 50%, FVC% pred < 80%, FEV1/FVC < 65%). No significant differences were observed in FeNO levels or overall adverse event incidence (P > 0.05). BALF analysis in 72 study patients identified 43 distinct pathogens (detection rate: 39.8%), predominantly bacterial species (72.1%). Adjunctive BAL significantly improved lung function, especially in small airways, without increasing adverse reactions, demonstrating a favorable safety profile in patients with uncontrolled allergic asthma, supports BAL's potential as a therapeutic procedure.

  • Open Access

    The management of type 2 inflammatory respiratory diseases: a Chinese expert consensus [2024]

    by Nan Jia, Meiling Jin, Yun Liu, Nan Su, Ying Sun, Wei Tang, Gang Wang, Hua Xie, Jiaxing Xie, Min Xie, et al.

    Expert Consensus The management of type 2 inflammatory respiratory diseases: a Chinese expert consensus [2024] Nan Jia, Meiling Jin, Yun Liu, Nan Su, Ying Sun, Wei Tang, Gang Wang, Hua Xie, Jiaxing Xie, Min Xie, Xin Yao, Huanping Zhang, Ruchong Chen, Chuntao Liu, Jing Li; on behalf of Respiratory Allergy Disease Group, the Chinese Allergy Society


  • Top Cited Papers
    Open Access

    Chronic airway inflammatory diseases and e-cigarette use: a review of health risks and mechanisms

    by Xing Yang, Wenqi Che, Lu Zhang, Huanping Zhang, Xiaoxue Chen

    Chronic airway inflammatory diseases, which primarily include chronic obstructive pulmonary disease (COPD), asthma, allergic rhinitis, and chronic sinusitis, continue to have a high global prevalence, highlighting their significant public health impact. Concurrently, the use of e-cigarettes (tobacco e-cigarettes) has been rising worldwide, with many users perceiving them as a safer alternative to traditional cigarettes. However, accumulating evidence from international studies suggests that e-cigarettes pose substantial health risks. This review aims to explore recent research on the relationship between e-cigarette use and chronic airway inflammatory diseases. The findings indicate that e-cigarette usage increases the risk of developing these conditions. Specifically, studies have shown that e-cigarettes exacerbate airway inflammatory responses, elevate levels of type 2 inflammatory cytokines such as IL-4, IL-5, and IL-13, increase cellular oxidative stress, and impair lung function. These mechanisms may collectively contribute to an increased risk of chronic airway inflammatory diseases potentially associated with e-cigarette use.


  • IL-10 signaling modulates PRKN methylation and influences STAT3 activity to drive regulatory macrophage differentiation

    by Lihuan Wang, Lingzhi Xu, Shuo Song, Lihua Mo, Le Liu, Hanqing Zhang, Xiaojun Xiao, Aizhi Zhang, Huanping Zhang, Pingchang Yang


  • Nemo mRNA vaccination improves airway barrier function in mice with airway allergy

    by Xianhai Zeng, Lihuan Wang, Xiwen Zhang, Haoyue Zheng, Shuo Song, Tao Xu, Huanping Zhang, Pingchang Yang


  • Open Access

    Direct exposure to CpG and specific antigens mitigate airway allergy through modulating dendritic cell properties

    by Aizhi Zhang, Lihua Mo, Xiaoxue Chen, Ping Tang, Yu Liu, Wenkai Zhang, Cheng Zhang, Cailing Wang, Huanping Zhang, Pingchang Yang


  • Open Access

    Recent developments in the immunopathology of COVID‐19

    by Huan‐Ping Zhang, Yuan‐Li Sun, Yan‐Fen Wang, Duygu Yazici, Dilek Azkur, Ismail Ogulur, Ahmet Kursat Azkur, Zhao‐Wei Yang, Xiao‐Xue Chen, Ai‐Zhi Zhang, et al.

    There has been an important change in the clinical characteristics and immune profile of Coronavirus disease 2019 (COVID‐19) patients during the pandemic thanks to the extensive vaccination programs. Here, we highlight recent studies on COVID‐19, from the clinical and immunological characteristics to the protective and risk factors for severity and mortality of COVID‐19. The efficacy of the COVID‐19 vaccines and potential allergic reactions after administration are also discussed. The occurrence of new variants of concerns such as Omicron BA.2, BA.4, and BA.5 and the global administration of COVID‐19 vaccines have changed the clinical scenario of COVID‐19. Multisystem inflammatory syndrome in children (MIS‐C) may cause severe and heterogeneous disease but with a lower mortality rate. Perturbations in immunity of T cells, B cells, and mast cells, as well as autoantibodies and metabolic reprogramming may contribute to the long‐term symptoms of COVID‐19. There is conflicting evidence about whether atopic diseases, such as allergic asthma and rhinitis, are associated with a lower susceptibility and better outcomes of COVID‐19. At the beginning of pandemic, the European Academy of Allergy and Clinical Immunology (EAACI) developed guidelines that provided timely information for the management of allergic diseases and preventive measures to reduce transmission in the allergic clinics. The global distribution of COVID‐19 vaccines and emerging severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants with reduced pathogenic potential dramatically decreased the morbidity, severity, and mortality of COVID‐19. Nevertheless, breakthrough infection remains a challenge for disease control. Hypersensitivity reactions (HSR) to COVID‐19 vaccines are low compared to other vaccines, and these were addressed in EAACI statements that provided indications for the management of allergic reactions, including anaphylaxis to COVID‐19 vaccines. We have gained a depth knowledge and experience in the over 2 years since the start of the pandemic, and yet a full eradication of SARS‐CoV‐2 is not on the horizon. Novel strategies are warranted to prevent severe disease in high‐risk groups, the development of MIS‐C and long COVID‐19.